72% reduction in hospitalisation from monoclonal antibodies, page-12

...notice how the trial is placebo controlled and yet they are reporting ongoing results. I am almost frutstrated by MSB's adherence to very tight, inependent testing, where others are happy to report ongoing results on blind studies (and arguably taint the eventual results). MSB's results will be far tighter in the long run of course.

Here's a more detailed release by the company:

https://investor.lilly.com/news-releases/news-release-details/lilly-announces-proof-concept-data-neutralizing-antibody-ly

I personally don't see it threatening Rem-L's market prospects in terms of ARDS (we are of course treating the moderate and severe cases that this treatment appears to have still exhibited after treatment) and given costing, dosaging and production issues, see it as an adjunct to MSB's REM-L rather than competition. Personally I am grateful for anything that helps groups like Nursing staff (the basis of the study).

https://clinicaltrials.gov/ct2/show/NCT04497987

Simply speaking, this helps keep serious cases developing, MSB comes in and clears up those serious ARDS related cases where it fails or hasn't been administered successfully.